GSK’s 5-in-1 Meningococcal Vaccine Under FDA Review

GlaxoSmithKline (GSK) has released an update.

GlaxoSmithKline (GSK) has announced that the US FDA is reviewing its 5-in-1 meningococcal ABCWY vaccine candidate, aiming to simplify immunization by reducing the number of injections needed. The vaccine, which met all primary endpoints in a pivotal phase III trial, could potentially enhance vaccination coverage and lower the risk of invasive meningococcal disease, particularly among adolescents. The FDA’s decision is expected by February 14, 2025.

For further insights into GSK stock, check out TipRanks’ Stock Analysis page.